Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
opioid receptor kappa antagonist · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| opioid receptor kappa antagonist | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| opioid receptor kappa antagonist | DRUG | Starting dose of 2 mg, administered orally, once. The potential dose range for this study is 0.2 mg to 30 mg |
Inclusion Criteria: * Healthy male or female * Have clinical laboratory tests within normal reference ranges * Have arterial and venous access sufficient to allow blood sampling Exclusion Criteria: * Currently enrolled in, or discontinued within the last 30 days from a clinical trial * History of...
Opioid receptor kappa antagonist is an investigational small molecule being studied for the treatment of alcohol dependence. It is in Phase 1 clinical development and has not been approved by the FDA. The drug is intended to act on the kappa opioid receptor, though its exact mechanism in alcohol dependence is still under investigation.
Opioid receptor kappa antagonist targets the kappa opioid receptor. By blocking this receptor, the drug may modulate brain pathways involved in alcohol dependence. However, the specific therapeutic effects and clinical benefits are still being evaluated in early-stage clinical trials.
Opioid receptor kappa antagonist is being developed by Eli Lilly and Company, a pharmaceutical company traded on the NYSE under the ticker symbol LLY. The drug is currently in Phase 1 clinical development for alcohol dependence.
Opioid receptor kappa antagonist is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug is still in the early stages of clinical testing for alcohol dependence.
Opioid receptor kappa antagonist has one completed Phase 1 clinical trial registered as NCT01232439, titled "A Study of Brain Receptor Occupancy in Healthy Subjects." The trial enrolled 13 participants in the United States and studied the drug's receptor occupancy in healthy volunteers, including those with alcohol dependence.